Marc Schapira

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11421979/publications.pdf

Version: 2024-02-01

331670 330143 1,973 40 21 37 citations h-index g-index papers 40 40 40 1514 docs citations times ranked citing authors all docs

| # | Article | IF | CITATIONS |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 1 | CCN1/CYR61-mediated meticulous patrolling by Ly6C ^{low} monocytes fuels vascular inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E4847-56. | 7.1 | 58 |
| 2 | Modulation of C1-Inhibitor and Plasma Kallikrein Activities by Type IV Collagen. International Journal of Biomaterials, 2012, 2012, 1-5. | 2.4 | 1 |
| 3 | Gas6 deficiency in recipient mice of allogeneic transplantation alleviates hepatic graft-versus-host disease. Blood, 2010, 115, 3390-3397. | 1.4 | 9 |
| 4 | Associations of serum EBV DNA and gammopathy with postâ€transplant lymphoproliferative disease. Clinical Transplantation, 2009, 23, 74-82. | 1.6 | 18 |
| 5 | P-selectin Glycoprotein Ligand-1 Decameric Repeats Regulate Selectin-dependent Rolling under Flow Conditions. Journal of Biological Chemistry, 2008, 283, 28536-28545. | 3.4 | 17 |
| 6 | Role of Gas6 in erythropoiesis and anemia in mice. Journal of Clinical Investigation, 2008, 118, 583-96. | 8.2 | 84 |
| 7 | Evolutionary conservation of P-selectin glycoprotein ligand-1 primary structure and function. BMC Evolutionary Biology, 2007, 7, 166. | 3.2 | 33 |
| 8 | Targeted Disruption of GAS6-Mertk Pathway Leads to Defects in Physiological Clearance of Expelled Nuclei from Erythroblasts by Bone Marrow Macrophages Blood, 2007, 110, 1708-1708. | 1.4 | 1 |
| 9 | Gas6 and Its Receptors Are Implicated in Sepsis as Modulators of Innate Immunity Blood, 2007, 110, 2409-2409. | 1.4 | O |
| 10 | Role of the growth arrest-specific gene 6 (gas6) product in thrombus stabilization. Blood Cells, Molecules, and Diseases, 2006, 36, 373-378. | 1.4 | 26 |
| 11 | Lipid raft adhesion receptors and Syk regulate selectin-dependent rolling under flow conditions. Blood, 2006, 108, 3352-3359. | 1.4 | 87 |
| 12 | Role of Growth Arrest-Specific Gene 6 Product (Gas6) in Severe Sepsis Blood, 2006, 108, 1640-1640. | 1.4 | 0 |
| 13 | Human tonsil implants xenotransplanted in SCID mice display broad lymphocytic diversity and cellular activation profile similar to those in the original lymphoid organ. Xenotransplantation, 2005, 12, 38-48. | 2.8 | 6 |
| 14 | Regulation of PSGL-1 Interactions with L-selectin, P-selectin, and E-selectin. Journal of Biological Chemistry, 2005, 280, 5378-5390. | 3.4 | 63 |
| 15 | Inhibition of plasma kallikrein by C1-inhibitor: role of endothelial cells and the amino-terminal domain of C1-inhibitor. Thrombosis and Haemostasis, 2004, 92, 1277-1283. | 3.4 | 23 |
| 16 | Molecular Basis of Leukocyte Rolling on PSGL-1. Journal of Biological Chemistry, 2003, 278, 37-47. | 3.4 | 68 |
| 17 | Haemolytic onset of Wilson disease in a patient with homozygous truncation of ATP7B at Arg1319. British Journal of Haematology, 2001, 114, 230-232. | 2.5 | 15 |
| 18 | Human Peripheral Blood Leukocyte Engraftment into SCID Mice: Critical Role of CD4+ T Cells. Cellular Immunology, 2001, 211, 8-20. | 3.0 | 7 |

| # | Article | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------|
| 19 | Epstein-Barr virus-dependent lymphoproliferative disease: critical role of IL-6. European Journal of Immunology, 2000, 30, 2065-2073. | 2.9 | 29 |
| 20 | C1 Inhibitor Cross-linking by Tissue Transglutaminase. Journal of Biological Chemistry, 2000, 275, 14558-14562. | 3.4 | 14 |
| 21 | Inhibition of Selectin-mediated Cell Adhesion and Prevention of Acute Inflammation by Nonanticoagulant Sulfated Saccharides. Journal of Biological Chemistry, 2000, 275, 34818-34825. | 3.4 | 67 |
| 22 | Acute Myeloid Leukemia in the Elderly: Results of an Individualized Approach in Two Centres. Leukemia and Lymphoma, 2000, 39, 521-530. | 1.3 | 7 |
| 23 | Monocyte Adhesion to Activated Aortic Endothelium: Role of L-Selectin and Heparan Sulfate Proteoglycans. Journal of Cell Biology, 1997, 136, 945-956. | 5.2 | 124 |
| 24 | Regulation of C1-Inhibitor Function by Binding to Type IV Collagen and Heparin. Biochemical and Biophysical Research Communications, 1997, 230, 597-601. | 2.1 | 18 |
| 25 | Serpins Are Suicide Substrates: Implications for the Regulation of Proteolytic Pathways. Seminars in Thrombosis and Hemostasis, 1994, 20, 410-416. | 2.7 | 21 |
| 26 | The Mechanism by Which Serpins Inhibit Thrombin and Other Serine Proteinasesa. Annals of the New York Academy of Sciences, 1994, 714, 13-20. | 3.8 | 8 |
| 27 | The role of conformational change in serpin structure and function. BioEssays, 1993, 15, 461-467. | 2.5 | 101 |
| 28 | Structure and Mechanism of Action of Serpins. Hematology/Oncology Clinics of North America, 1992, 6, 1393-1408. | 2.2 | 56 |
| 29 | Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate. Biochemistry, 1991, 30, 8876-8882. | 2.5 | 190 |
| 30 | Serine protease inhibitors (serpins). Trends in Cardiovascular Medicine, 1991, 1, 146-151. | 4.9 | 12 |
| 31 | Studies on the human plasma kallikrein-kinin system: \hat{l}_{\pm} -kallikrein does not directly activate blood neutrophils. Thrombosis Research, 1989, 55, 109-119. | 1.7 | 3 |
| 32 | [16] C Inhibitor: The predominant inhibitor of plasma kallikrein. Methods in Enzymology, 1988, 163, 179-185. | 1.0 | 15 |
| 33 | Major Inhibitors of the Contact Phase Coagulation Factors. Seminars in Thrombosis and Hemostasis, 1987, 13, 69-78. | 2.7 | 30 |
| 34 | Biochemistry and Pathophysiology of Human Cl Inhibitor: Current Issues. Complement (Basel,) Tj ETQq0 0 0 rgBT | /Qverlock | 10 Tf 50 142 |
| 35 | Prekallikrein Activation and High-Molecular-Weight Kininogen Consumption in Hereditary Angioedema. New England Journal of Medicine, 1983, 308, 1050-1053. | 27.0 | 196 |
| 36 | High molecular weight kininogen or its light chain protects human plasma kallikrein from inactivation by plasma protease inhibitors. Biochemistry, 1982, 21, 567-572. | 2.5 | 72 |

| # | Article | IF | CITATION |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----------|
| 37 | Contribution of Plasma Protease Inhibitors to the Inactivation of Kallikrein in Plasma. Journal of Clinical Investigation, 1982, 69, 462-468. | 8.2 | 199 |
| 38 | Inactivation of Factor XIa by Plasma Protease Inhibitors. Journal of Clinical Investigation, 1982, 69, 844-852. | 8.2 | 126 |
| 39 | Protection of human plasma kallikrein from inactivation by c.hivin.1 inhibitor and other protease inhibitors. The role of high molecular weight kininogen. Biochemistry, 1981, 20, 2738-2743. | 2.5 | 113 |
| 40 | REGULATION OF THE FORMATION AND INHIBITION OF HUMAN PLASMA KALLIKREIN*. Annals of the New York Academy of Sciences, 1981, 370, 261-270. | 3.8 | 10 |